Saturday, November 10th, 2007 8:00 a.m. – 5:00 p.m. followed by a cocktail reception until 6:30 p.m.
Venue: The Grande Ballroom
7:00 am |
Registration Opens |
7:00 am -7:45 am |
Breakfast |
|
Introduction |
8:00 am -8:15 am |
David Maggs, MD
Amylin Pharmaceuticals |
Welcome |
8:15 am -8:45 am |
Alain Baron, MD
Amylin Pharmaceuticals |
Amylin: One Score Year and Then |
Discovery to Clinical Drug Candidate |
8:45 am -9:30 am |
Michael Hanley, PhD
Amylin Pharmaceuticals |
Building, Understanding and Leveraging a Peptide Library |
9:30 am -10:15 am |
Richard Dimarchi, PhD
Indiana University |
Application of Chemical Biotechnology to the Optimization of Protein Therapeutics |
10:15 am -10:30 am |
Coffee break |
|
Into the Clinic |
10:30 am -11:15 am |
Per Cantor, MD, PhD
Ferring Pharmaceuticals |
Degarelix: a novel GnRH antagonist for the treatment of prostate cancer |
11:15 am -12:00 pm |
Charles Cochrane, MD
The Scripps Research Institute |
KL-4 Surfactant – Form to Function |
Noon -12:45 pm |
Lunch |
|
Into the Market |
12:45 am -1:30 pm |
Brad DeHoff, PhD
Roche Colorado Corp. |
The Commercialization of Fuzeon® API |
1 :30 pm -2:15 pm |
Andrew Young, MD, PhD
Amylin Pharmaceuticals |
The Beta Cell Hormone Amylin: Discovery and Clinical Application |
2:15 pm – 2:30 pm |
Coffee break |
|
Peptide Systems for the Future |
2:30 pm - 3:15 pm |
Thue Schwartz, MD
7TM Pharma, University of Copenhagen |
"Ynot Y2 and Y4 Peptide Agonists for Treatment of Diabetes and Obesity?” |
3:15 pm - 4:00 pm |
Steve Bloom, MD
Imperial College, London |
Oxyntomodulin or Products of the PYY Preproglucagon gene |
4:00 pm - 4:45 pm |
Jeff Friedman, MD, PhD
The Rockefeller University |
The Therapeutic Opportunities for Leptin: An Ongoing Play in Three or More Acts |
Closing |
4:45 pm - 5:00 pm |
Pierre Rivière, PhD
Ferring Pharmaceuticals |
Closing Remarks |
5:00 pm |
Networking |
|
